UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Income from Continuing Operations of 23574000.0 for Q1 2026, up 46.23% year-on-year from 16121083.14 in Q1 2025, and down 361.93% on a QoQ basis from 9000000.0 in Q4 2025.
UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Income from Continuing Operations for 10 consecutive years, with 23574000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 46.23% year-over-year to 23574000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97861000.0 (up 8.6% YoY) and the FY2025 annual result came in at 118130000.0, down 23.68% from the prior year.
- Income from Continuing Operations eased to 23574000.0 in Q1 2026 per URGN's latest filing, from 9000000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for URGN reached as high as 9000000.0 in Q4 2025 and fell as low as 49940000.0 in Q2 2025.
- A 5-year average of 23300352.94 and a median of 25831000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 1284.97% — and 2025, when it jumped 246.34%.
- Year by year, Income from Continuing Operations stood at 2267000.0 in 2022, then soared by 122.89% to 519000.0 in 2023, then sank by 1284.97% to 6150000.0 in 2024, then soared by 246.34% to 9000000.0 in 2025, then tumbled by 361.93% to 23574000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 23574000.0, 9000000.0, and 33347000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -23.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.57 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | -33.35 Mn |
| Jun 30, 2025 | -49.94 Mn |
| Mar 31, 2025 | -43.84 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -23.67 Mn |
| Jun 30, 2024 | -33.40 Mn |
| Mar 31, 2024 | -32.29 Mn |
| Dec 31, 2023 | 519,000.00 |
| Sep 30, 2023 | -21.88 Mn |
| Jun 30, 2023 | -24.14 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -2.27 Mn |
| Sep 30, 2022 | -25.83 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -28.39 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -30.21 Mn |
| Jun 30, 2021 | -26.22 Mn |